← All trials
NCT05555862
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Apr 30, 2024
- First posted
- Sep 27, 2022
- Last posted
- Nov 8, 2022
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Frantz MedicalLead sponsor
- Amarex Clinical ResearchCollaborator
- Anal Dysplasia Clinic MidWestCollaborator
- University of California, San FranciscoCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.